Gerresheimer completes Centor sale. Gerresheimer stock falls 3.50 percent

Published on 10/01/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA rose to EUR 102.00 million in the second quarter from EUR 67.00 million. Gerresheimer stock costs EUR 27.87 on October 1, 2026 after EUR 28.88.

Automatisierte Glasampullen-Produktionslinie in steriler Pharmafabrik — Gerresheimer AG mit ISIN DE000A0LD6E6 produziert Glasampullen in hochautomatisierter, steriler Pharmaverpackungsfertigung mit modernster Anlagentechnik, Illustration mit AI erstellt.

Gerresheimer (ISIN DE000A0LD6E6) completed the sale of its US subsidiary Centor on October 1, 2026, while its stock was trading at EUR 27.87 at Lang & Schwarz at 1:47 p.m. CEST, down 3.50 percent versus the prior close of EUR 28.88. As Finanznachrichten reported on October 1, 2026, the proceeds will be used to reduce debt.

Centor closes in two months

The transaction follows agreements signed on July 29, 2026, covering Centor and Gerresheimer's global Primary Packaging Plastics business. The combined enterprise value was EUR 1.50 billion, with Centor representing half of that amount, according to Finanznachrichten.

The remaining Primary Packaging Plastics sale is expected to close in the first half of 2027. That timeline makes debt reduction and refinancing central to the next stage of the portfolio reshaping.

Quarterly recovery meets pressure

Gerresheimer's preliminary second-quarter 2026 revenue reached EUR 578.00 million, down from EUR 614.00 million in the second quarter of 2025, a decline of 5.86 percent. Adjusted EBITDA increased to EUR 102.00 million from EUR 67.00 million in the first quarter of 2026, a gain of 52.24 percent.

The figures came from the preliminary results published on September 30, 2026, which also showed an adjusted EBITDA margin of 17.60 percent in the second quarter. FT reported that first-half 2026 adjusted EBITDA totaled EUR 168.00 million, compared with EUR 224.00 million in the first half of 2025.

Guidance points to second half

Gerresheimer kept its 2026 outlook and expects revenue in the lower half of the EUR 2.30 billion to EUR 2.40 billion range, alongside an adjusted EBITDA margin of 17.00 percent to 18.00 percent. The company also targets free cash flow before mergers and acquisitions between negative EUR 50.00 million and negative EUR 100.00 million, as reported by Investing.com.

The company expects the second half of 2026 to be stronger than the first. Investors therefore face a clear test: asset-sale proceeds must lower leverage while the improved quarterly operating trend must continue.

Stock tests the yearly range

Gerresheimer stock was trading at EUR 27.87 at Lang & Schwarz on October 1, 2026 at 1:47 p.m. CEST, minus 3.50 percent versus the Lang & Schwarz prior close of EUR 28.88 on September 30, 2026. The 52-week range was EUR 14.83 to EUR 38.32, placing the price 27.27 percent below the high.

The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.